• Ordered DNA Nanostructures Advance Enzymatic DNA Synthesis

  2026-08-05

  A new study introduces a tetrahedral DNA nanostructure interface that significantly improves the efficiency and accuracy of enzymatic oligonucleotide synthesis (EOS). By enhancing enzyme accessibility and reducing synthesis errors, this approach supports high-fidelity DNA assembly, enabling advances in DNA storage and synthetic biology.

• 0.4% Trypan Blue Solution: Technical Guide for Cell Viabilit

  2026-08-04

  0.4% Trypan Blue Solution enables rapid, visual discrimination of live and dead cells, supporting accurate viability measurements in cell culture and cytotoxicity workflows. It is intended for research-only uses and should not be applied in diagnostic or clinical settings.

• D-N-Acetylgalactosamine: Technical Use in Glycoprotein Analy

  2026-08-04

  D-N-Acetylgalactosamine addresses the need for a high-purity, water-soluble standard in the analysis of glycoprotein constituents, especially within neurological research and brain heteropolysaccharide studies. It should not be used in protocols that require ethanol solubility or long-term storage of working solutions, ensuring that researchers follow precise handling and workflow parameters for reproducible results.

• Dissecting N-Type Ca Channel Blockade by Spider Toxin v-Agat

  2026-08-03

  Sidach and Mintz (2000) redefined the pharmacological profiling of neuronal high-threshold calcium channels using v-agatoxin-IVA, clarifying its selectivity and revealing the complexity of channel subtypes in mammalian neurons. Their findings have direct implications for experimental approaches probing calcium-dependent signaling, secretion, and channel subtype classification.

• GSK J4 HCl: Advancing JMJD3 Inhibition in Inflammatory and P

  2026-08-03

  Explore how GSK J4 HCl, a potent JMJD3 inhibitor, enables researchers to dissect histone methylation dynamics in inflammation and pregnancy immunity. This article delivers distinct insights into assay design, translational relevance, and protocol optimization.

• AP-2α Suppresses MGMT to Reverse TMZ Resistance in Recurrent

  2026-08-02

  This study demonstrates that transcription factor AP-2α directly downregulates MGMT expression, sensitizing recurrent glioblastoma (GBM) cells to temozolomide (TMZ) by enhancing DNA damage. These findings clarify the transcriptional control underlying MGMT-mediated chemoresistance and point to new strategies for overcoming therapeutic resistance in aggressive brain tumors.

• Ruthenium Red: Redefining Ca2+ Transport Inhibition in Mecha

  2026-08-01

  Explore how Ruthenium Red, a premier Ca2+ transport inhibitor, uniquely advances mechanical stress and cytoskeleton-dependent autophagy research. This guide provides mechanistic insights, protocol parameters, and critical interpretation for cutting-edge calcium signaling studies.

• HyperPFU™ High-Fidelity DNA Polymerase: Practical PCR Guidan

  2026-07-31

  HyperPFU™ high-fidelity DNA polymerase addresses the persistent challenge of accurate PCR amplification of long, GC-rich, or otherwise difficult DNA templates. It is optimal for workflows requiring blunt-ended, high-fidelity PCR products, but should not be used for applications needing 3'-A overhangs or sticky ends.

• AMPK–SQSTM1 Feedback Enhances Dual Antioxidant Defense in Tu

  2026-07-31

  The referenced study uncovers a double-positive feedback loop between AMPK and SQSTM1/p62 under metabolic stress, enabling synergistic activation of AMPK and NFE2L2/NRF2 antioxidant pathways. These findings clarify the molecular basis for tumor adaptation, particularly in lung cancer with co-occurring STK11 and KEAP1 mutations, and suggest new avenues for targeted metabolic interventions.

• Ruthenium Red: Unveiling Mechanotransduction in Cytoskeleton

  2026-07-30

  This thought-leadership article explores how Ruthenium Red, a potent Ca2+ transport inhibitor from APExBIO, is revolutionizing cytoskeleton-dependent autophagy research under mechanical stress. Integrating mechanistic insights and strategic guidance, we bridge foundational calcium signaling research with the rapidly evolving landscape of mechanotransduction, providing actionable intelligence for translational researchers.

• Perospirone (SM-9018 Free Base): Applied Workflows in Schizo

  2026-07-30

  Perospirone (SM-9018 free base) bridges advanced neuropsychiatric disorder modeling with innovative cardiovascular assays, uniquely combining high-affinity receptor antagonism and Kv1.5 channel inhibition. This guide translates new mechanistic findings into actionable experimental protocols and troubleshooting strategies, empowering researchers to maximize data reliability and translational relevance.

• Structural Basis of ASCH Domain Proteins in N4-Acetylcytidin

  2026-07-29

  Meng et al. provide the first high-resolution structural analysis of ASCH domain-containing proteins involved in N4-Acetylcytidine (ac4C) metabolism. Their work clarifies the catalytic specificity of EcYqfB, revealing it acts on free ac4C nucleoside but not on RNA-incorporated modifications, refining the mechanistic understanding of nucleotide processing in RNA epigenetics research.

• BAPTA-AM (B4758): Technical Guide for Calcium Chelation Assa

  2026-07-29

  BAPTA-AM is a cell-permeable calcium chelator designed for precise and rapid modulation of intracellular Ca²⁺, making it suitable for assays targeting calcium signaling, apoptosis, and neuroprotection. It is not appropriate for workflows requiring magnesium selectivity or prolonged reagent stability due to its selectivity profile and solubility constraints. Researchers should strictly follow handling and control procedures to ensure reliable results.

• AMPK–SQSTM1 Feedback Synergizes Antioxidant Defense in Stres

  2026-07-28

  This study uncovers a double-positive feedback loop between AMPK and SQSTM1/p62, driving dual activation of AMPK and NFE2L2/NRF2 under metabolic stress. The findings elucidate how tumor cells coordinate antioxidant defense and metabolic adaptation, offering mechanistic insight into the significance of co-occurring STK11 and KEAP1 mutations in cancer.

• Dabigatran Etexilate: Oral Direct Thrombin Inhibitor for Str

  2026-07-28

  The reference study establishes dabigatran etexilate as the first oral direct thrombin inhibitor, demonstrating rapid, predictable anticoagulant effects without the frequent monitoring required by traditional agents. This innovation addresses major clinical challenges in stroke and venous thromboembolism prevention, especially for patients with atrial fibrillation.

8038 records 3/536 page Previous Next 12345 下5页 Last page